Trial Profile
AN OPEN-LABEL, RANDOMIZED, PHASE 2 STUDY COMPARING TAS-102 VERSUS TOPOTECAN OR AMRUBICIN IN PATIENTS REQUIRING SECONDLINE CHEMOTHERAPY FOR SMALL CELL LUNG CANCER THAT IS REFRACTORY OR SENSITIVE TO FIRST-LINE PLATINUM-BASED CHEMOTHERAPY [STUDIO DI FASE 2, IN APERTO, RANDOMIZZATO VOLTO A CONFRONTARE TAS-102 RISPETTO A TOPOTECAN O AMRUBICINA IN PAZIENTI CHE NECESSITANO DI CHEMIOTERAPIA DI SECONDA LINEA PER IL CARCINOMA POLMONARE A PICCOLE CELLULE REFRATTARIO O SENSIBILE ALLA CHEMIOTERAPIA DI PRIMA LINEA A BASE DI PLATINO].
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 31 Oct 2017
Price :
$35
*
At a glance
- Drugs Tipiracil/trifluridine (Primary) ; Amrubicin; Topotecan
- Indications Small cell lung cancer
- Focus Therapeutic Use
- Sponsors Taiho Pharmaceutical
- 11 Jul 2014 Status changed from suspended to discontinued as reported by ClinicalTrials.gov record.
- 08 Jan 2014 Status changed from recruiting to suspended as reported by ClinicalTrials.gov record.
- 19 Jul 2013 Planned end date (Oct 2015) added as reported by ClinicalTrials.gov.